pd-1

RMP1-14 is an IgG-like immunoglobulin antibody against mouse PD-1 that can block PD-1 PD-L1 signaling; its isotype control antibody is Mouse IgG2a kappa, Isotype Control.

Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.

Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and others.

Peresolimab, a humanized IgG1-κ antibody, targets PD-1 and may activate physiological immune inhibitory pathways, thereby restoring immune homeostasis [1] [2].

Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.

Rosnilimab, a humanized IgG1-κ antibody, specifically targets PD-1 [1] [2].

Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1 PD-L1 relapsed refractory metastatic solid tumors [1].

Rezilimab is a bispecific antibody that targets PD-1 PD-L1 and mediates antibody-dependent cell cytotoxicity (ADCC) in cancer research [1] [2].

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Anti-PD-1 Antibody (8P789) is a mouse (varialbe region) human (kappa IgG1 constant) chimeric monoclonal antibody targeting Human PD-1.

PD-1 PD-L1-IN-20 is a small molecule inhibitor of PD-1 PD-L1 protein-protein interaction, blocking the interaction with an IC50 of 5.29 nM. PD-1 PD-L1-IN-20 can be used to study cancer, infectious diseases, and autoimmune diseases.

Anti-MousePD-1Antibody (J43) is an IgG antibody derived from mice, targeting PD-1 and originating from American hamsters. The isotype control for Anti-MousePD-1Antibody (J43) is Armenian hamsterIgG, Isotype Control.

The Anti-MousePD-1Antibody (29F.1A12) is an antibody derived from rat IgG2akappa that targets PD-1 in mice. The isotype control for Anti-MousePD-1Antibody (29F.1A12) is RatIgG2akappa, Isotype Control.

Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.

Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.

Anti-Mouse Human phosphorylated PD-1 CD279 Antibody (407.6G12) is an IgG2a, κ antibody inhibitor derived from mice, targeting phosphorylated PD-1 CD279 in both mice and humans.

Anti-Mouse PD-1 Antibody (D265A) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting mouse PD-1.

TSR-033 is a human IgG4 antibody with high affinity for LAG-3 (lymphocyte activation gene-3), a co-receptor linked to diminished T cell activity, frequently co-expressed with PD-1. It bolsters T cell function and augments PD-1 inhibition both in vitro and in vivo, demonstrating anti-tumor activity [1].

Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.

Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.

Sugemalimab, a fully human, full-length, IgG4 monoclonal antibody (mAb) targeting programmed death ligand 1 (PD-L1), exhibits anticancer activities and is applicable in non-small cell lung cancer research [1].

Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.

Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Latikafusp initiates and prolongs cytotoxicity and memory T-cell activity and induces the generation of immunogenicity-mediated responses.